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successfully be used for prevention and treatment of acute 
radiodermatitis.  
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Purpose/Objective: Radiotherapy is useful for the treatment of MALT 
lymphoma of the ocular adnexa and is the first choice for this disease. 
We investigated the long-term follow-up results of radiotherapy for 
MALT lymphoma of the ocular adnexa. 
Materials and Methods: Twenty-four patients with MALT lymphoma of 
the ocular adnexa were treated with radiotherapy alone. The disease 
arose from the conjunctiva in 18 patients (10 with bilateral 
involvement), and from the retrobulbar space in 6 patients (1 with 
bilateral involvement). The median follow-up of the surviving patients 
was 70 months (range, 6-157). The histological diagnoses obtained via 
an incisional biopsy in all cases were categorized according to the 
criteria established by the WHO classification. During the staging 
work-up, gallium scans, computed tomography of the chest and 
abdomen, and FDG-PET were performed for all patients. Patients with 
IAE or IAE2 disease according to the American Joint Committee on 
Cancer TNM Classification were treated with radiotherapy alone. 
Lesions confined to the conjunctiva were treated with a single 
anterior direct field using a 6-12 MeV electron beam. The entire 
bulbar and palpebral conjunctiva were treated. Retrobulbar tumors 
were irradiated with 18 MeV electron or 6-MV X-rays. The clinical 
target volume was the entire orbital cavity. A median dose per 
fraction of 2.0Gy (range 1.8-2.5) was administered, with the total 
dose ranging between30 and 54Gy (median, 38Gy). Lead eye shields 
were used for radiotherapy of conjunctival lymphoma. Lens protection 
was not used for radiotherapy of retrobulbar lymphoma except for one 
patient.  
Results: All patients with MALT lymphoma achieved a CR or 
unconfirmed CR (CRu). Two patients died of other disease.  
One patient died of lung cancer and another patient died of 
progressive supranuclear palsy. The 5-and 10-year overall survival 
rates of all patients with MALT lymphoma were 100% and 90%, 
respectively. The 5-and 10-year cause-specific survival rates were 
100% and 100%, respectively. Seven eye-balls developed delayed 
toxicity. Four eye-balls with conjunctival lymphoma experienced dry 
eye syndrome, and four eye-balls developed cataracts. One patient 
with retrobulbar lymphoma experienced both dry eye syndrome and 
cataracts. The vision of patients with cataracts was restored by 
surgery. In seven eye-balls, the radiation dose had been 40Gy or 
more.  
Conclusions: Excellent local control and survival can be achieved for 
patients with MALT lymphoma of the ocular adnexa using radiotherapy 
alone. As a dose of more than 30Gy develops dry eye syndrome or 
cataract, the dose must not exceed 30Gy for safe treatment of MALT 
lymphoma of the ocular adnexa. At present, based on our study and 
previous studies, we administer a radiation dose of 30.6Gy with a 
fraction size of 1.8Gy for MALT lymphoma of ocular adnexa treatment. 
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Purpose/Objective: The presence of an air filled ionization chamber 
in a surrounding medium introduces several fluence perturbations in 
high energy photon and electron beams which have to be accounted 
for. One of these perturbations, the displacement effect, may be 
corrected in two different ways: by a correction factor pdis or by the 
application of the concept of the effective point of measurement 
(EPOM). The latter means, that the volume averaged ionization within 
the chamber is not reported to the chambers reference point but to a 
different point, the so called effective point of measurement.  
Materials and Methods: Within this study the EPOM was determined 
for four different parallel plate and two cylindrical chambers in mega 
voltage electron beams using Monte Carlo simulations. The positioning 
of the chambers with this EPOM at the depth of measurement results 
in a largely depth independent residual perturbation correction.  
Results: For all parallel plate chambers the EPOM is independent on 
the energy of the primary electrons. Whereas for the Advanced Markus 
chamber the position of the EPOM coincides with the chambers 
reference point, it is shifted for the other parallel plate chambers 
several tenths of millimeters downstream the beam direction into the 
air filled cavity. For the cylindrical chambers there is an increasing 
shift of the EPOM with increasing electron energy. This shift is in 
upstream direction, i.e. away from the chambers reference point 
toward the focus. For the highest electron energy the position of the 
calculated EPOM is in fairly good agreement with there commendation 
given in common dosimetry protocols, for the smallest energy the 
calculated EPOM positions deviates about 30% from this 
recommendation.  
Conclusions: Besides the determination of the EPOM, the residual 
perturbation correction for all investigated chambers for the whole 
range of clinical used electron energies was calculated. The 
application of the proposed effective point of measurement will 
increase the accuracy of calculating depth dose data from measured 
depth ionization curves, especially for depth beyond the reference 
depth. 
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Purpose/Objective: Modulated arc therapy is becoming the common 
technique to deliver Stereotactic Radiotherapy. A double challenge 
arises with respect to its verification. Not only a dose plane should be 
measured but preferably the entire 3D dose distribution. And, since it 
includes steep gradient regions, this dose distribution should be 
obtained with a spatial resolution as high as possible. The aim of this 
study is to commission a new system which facilitates this procedure, 
and to evaluate the routine use of this new measuring device. 
Materials and Methods: Recently, a new approach to the measure of 
the 3D dose distribution arised with the introduction of the new 
Octavius 4D system (PTW). It consists of an ion chamber array 
embedded in a cylindrical phantom. The phantom is connected to an 
inclinometer that is attached to the gantry, so that the system is 
capable to rotate following the gantry orientation in such a way that 
the array is always perpendicular to the beam axis. Dose distribution 
and gantry angle are registered as a function of time. Provided with a 
set of percentage depth dose curves, previously measured and 
introduced in the system software, the system computes the dose 
distribution for each gantry angle and reconstructs the resulting 3D 
dose matrix. The system allows several options for the ion chamber 
array: the well-known 2D-Array seven29; its successor Octavius 
Detector 729; or the small field dedicated Octavius 1000 SRS array, 
which was used in this study, with 977 liquid filled, 2.3×2.3×0.5 mm3 
sized ion chambers covering a 11×11 cm2 area, with a 2.5 mm spacing 
in the central 5.5×5.5 cm2 region. The accelerators used were Varian 
Clinac iX and Varian TrueBeam with MLC 120HD. The TPS was Eclipse 
(version 10.0). The commissioning measurements consisted of the 
following tests: (1) Homogeneity of chamber response evaluated as 
the maximum deviation with respect to the mean for a uniform field; 
(2) Linearity, evaluated by fitting measured dose versus UM with a 
linear function; (3) Reproducibility, evaluated as the maximum 
difference between several measures with respect to the mean, for 
the same UM value; (4) Leakage current, pre- and post-irradiation; (5) 
Verification of typical SBRT clinical plans, evaluated by comparing 
TPS-calculated versus measured dose using 3D gamma index, with 3%, 
3 mm criteria. 
Results: (1) The homogeneity between chambers was 0.8%. (2) 
Linearity was found to be excellent, with an r2 value better than 
0.999. (3) The reproducibility was found to be 0.08%. (4) Leakage 
increases with previously measured dose and shows its largest 
variation for large fields. For a 10×10 cm2 field, it ranges from –0.35 
cGy/h to 1.18 cGy/h. (5) Verification of typical clinical plans showed 
a mean pass ratio of 94.6% (range 91.8%-96.4%). 
Conclusions: Octavius 4D system together with Octavius 1000 SRS 
array is an adequate tool in the routine patient-specific QA of SBRT 
VMAT IMRT treatment plans. 
 
